Elanco Animal Health Inc at JPMorgan Healthcare Conference Transcript
Good morning, everybody. I'm Chris Schott from JPMorgan and very pleased to be introducing Elanco today. From Elanco, we have the company's CEO, Jeff Simmons. If we think back to last year, the company presented shortly after its IPO. We had a very busy 2019, including the Bayer transaction announced over the summer, so very much looking forward to Jeff's comments and as we think about Elanco heading into 2020.
Thanks, Chris. Look forward to the opportunity to share a little bit of the exciting year we had in 2019 and looking forward in 2020. Of course, I'll make the disclaimer of forward-looking comments. Here's what I'd like to do today. No question an exciting time in our history as a company.
I'd like to cover 3 areas today. First, back to some of the compelling fundamentals of the industry that we're in, a little different than pharmaceuticals that is represented here today,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
